High Ki67 expression before docetaxel, cisplatin, and fluorouracil (TPF) neoadjuvant chemotherapy predicts better prognosis in patients with locally advanced oral squamous cell carcinoma
Autor: | Xin-yu Zhou, Gang Chen, Tong-chao Zhao, Yu Yao, Zhi-yuan Zhang, Zhi-hang Zhou, Lai-ping Zhong, Dong-wang Zhu |
---|---|
Rok vydání: | 2022 |
ISSN: | 0154-2931 |
DOI: | 10.21203/rs.3.rs-1998278/v1 |
Popis: | Background Patients with locally advanced oral squamous cell carcinoma (OSCC) failed to benefit from docetaxel, cisplatin and 5-fluorouracil (TPF) neoadjuvant chemotherapy prior to surgery and postoperative radiotherapy in our previous phase 3 trial (NCT01542931). The aim of the present study was to explore the prognostic value of Ki67 expression for individualized TPF neoadjuvant therapy. Methods Immunohistochemical staining of Ki67 was performed in the biopsies before treatment in the experimental arm of our previous phase 3 trial. A total of 65 patients with Ki67 expression below 25% or above 50% were retrospectively reviewed in this study. Kaplan‑Meier analysis, log-rank test and Cox proportional hazards model were used for survival analysis. Results Among the 65 patients enrolled in the study, the patients with high Ki67 expression (n = 41) before treatment exhibited higher overall survival (OS) (P = 0.041) and distant metastasis–free survival (DMFS) (P = 0.049) than those with low expression (n = 24). The 5-year OS of the two groups were 70.7% and 45.8% respectively (high vs low). Cox proportional hazards model showed that high Ki67 expression before TPF neoadjuvant chemotherapy had a positive impact on the OS (HR = 0.399, 95% CI: 0.178–0.893, P = 0.025). Conclusions High Ki67 expression before treatment could predict the survival benefits from TPF neoadjuvant chemotherapy prior to standard therapy in patients with locally advanced OSCC, which could act as a biomarker for individualized treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...